Symic Biomedical, Inc., a San Francisco, California-based platform therapeutic company, received a $1.5M Phase II SBIR grant.
The National Institutes of Health (NIH) provided the funding.
The company intends to use the funds to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures.
The two-year project, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), will allow Symic to perform additional preclinical efficacy studies and advance lead candidate SBCV-030, a new class of therapeutics intended to target the extracellular matrix (ECM), towards clinical development. The company, led by Ken Horne, Chief Executive Officer, will work in collaboration with Prabir Roy-Chaudhury, M.D., Ph.D., Division Director of Nephrology at the University of Arizona College of Medicine and Banner University Medical Center, Tucson and member of the Board of Advisors of the American Society of Nephrology.